Loading
WT
Windtree Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Fraser Craig, was filed 09 Oct 2024.
Windtree Therapeutics Inc: what insiders have been doing
Every trade that managers of Windtree Therapeutics Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at Windtree Therapeutics Inc has published a filing in the past twelve months. The most recent one dates from 9 October 2024.
Our records for Windtree Therapeutics Inc go back to 2016, with 18 purchases and no sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
47
Thresholds
n/a
Buy Volume
€42,783
18 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -99.5%Entry US$35.10 · Close at T+365 US$0.18
- -92.8%Entry US$16,749.02 · Close at T+365 US$1,206.00
- -88.7%Entry US$90,450.09 · Close at T+365 US$10,224.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$170.5k
EBITDA-US$1.5M-865% margin
Net income-US$5.5M0.0% margin
Valuation
PER (trailing)0.0x
Beta1.62
Balance sheet & cash
Market capUS$6.7k
Total debtUS$1.8M
Free Cash Flow-US$15.4M
Profitability & ownership
ROA-42.4%
% insiders0.0%
% institutions0.0%
Last declaration on 9 October 2024
Declarations47 total
5,431 shares@ US$0.909912.1% of flowCommon StockSEC:0001437749-24-030918:0
Canonical exit: 6 Jan 2025 (T+90)
2,500 shares@ US$1.01996.5% of flowCommon StockSEC:0001437749-23-026969:0
Canonical exit: 26 Dec 2023 (T+90)
2,500 shares@ US$0.905.7% of flowCommon StockSEC:0001437749-23-026828:0
Canonical exit: 25 Dec 2023 (T+90)
2,033 shares0Common StockSEC:0001437749-23-024844:0
2,300 shares0Common StockSEC:0001437749-23-024715:0
14,667 shares0Common StockSEC:0001437749-23-024712:0
45,867 shares0Common StockSEC:0001437749-23-024710:0
2,033 shares0Common StockSEC:0001437749-23-024714:0
15,867 shares0Common StockSEC:0001437749-23-024713:0
2,033 shares0Common StockSEC:0001437749-23-024716:0
1,497 shares@ US$1.776.5% of flowCommon StockSEC:0001437749-23-011245:0
Canonical exit: 25 Jul 2023 (T+90)
1,315 shares@ US$1.896.1% of flowCommon StockSEC:0001437749-23-011064:0
Canonical exit: 24 Jul 2023 (T+90)
99 shares0Common StockSEC:0001437749-23-005266:0
334 shares0Common StockSEC:0001437749-23-005268:0
99 shares0Common StockSEC:0001437749-23-005267:0
100 shares0Common StockSEC:0001437749-23-005270:0
1,112,308 shares@ US$0.1411100.0% of flowCommon StockSEC:0000899243-23-005992:0
2,500 shares@ US$0.37992.5% of flowCommon StockSEC:0001437749-22-017890:0
Canonical exit: 25 Oct 2022 (T+90)
3,000 shares@ US$0.3666100.0% of flowCommon StockSEC:0001437749-22-017793:0
Canonical exit: 24 Oct 2022 (T+90)
2,500 shares@ US$0.3742.5% of flowCommon StockSEC:0001437749-22-017791:0
Canonical exit: 24 Oct 2022 (T+90)
4,500 shares@ US$0.42794.9% of flowCommon StockSEC:0001437749-22-016607:0
Canonical exit: 28 Sept 2022 (T+90)
7,000 shares@ US$0.415448.24% mcap7.5% of flowCommon StockSEC:0001437749-22-016227:0
Canonical exit: 27 Sept 2022 (T+90)
5,000 shares0Common StockSEC:0001437749-22-014714:0
5,000 shares0Common StockSEC:0001437749-22-014719:0
5,000 shares0Common StockSEC:0001437749-22-014722:0
25 of 47 declarations
About Windtree Therapeutics Inc
Windtree Therapeutics Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market under the ticker WINT. Headquartered in Warrington, Pennsylvania, in the United States, the company historically built its profile around the development of therapies for severe cardiovascular and pulmonary conditions. Its principal executive offices house corporate administration, research and drug development, clinical operations, regulatory affairs, and quality functions, while the company also maintains an office in Taipei, Taiwan to support certain manufacturing-development and preclinical activities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/946486/000143774925012093/wint20241231_10k.htm))
From a business model perspective, Windtree has evolved from a focused respiratory/cardiopulmonary biotech into a more diversified development-stage company. Its lead product candidate is istaroxime, a first-in-class investigational drug being developed for cardiogenic shock and acute heart failure. The company’s earlier portfolio also included aerosolized KL4 surfactant assets such as lucinactant/AEROSURF, and its SEC filings show additional intellectual property and development work in areas such as rostafuroxin and early-stage oncology. That breadth matters, because Windtree’s economics are still driven primarily by pipeline optionality rather than recurring commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/946486/000143774925012093/wint20241231_10k.htm))
Read moreShow less
In competitive terms, Windtree remains a small-cap biotech with a high-risk, event-driven valuation profile. Its market position is not defined by scale or commercial market share, but by the potential clinical differentiation of istaroxime and by the company’s ability to fund development, secure partnerships, and convert assets into revenue-generating opportunities. Management has explicitly stated that istaroxime may offer a differentiated safety profile versus current therapies and has emphasized the unmet medical need in cardiogenic shock. That positioning is important, but it should be viewed through the lens of a development-stage company where regulatory milestones and capital access are decisive. ([sec.gov](https://www.sec.gov/Archives/edgar/data/946486/000143774925012093/wint20241231_10k.htm))
Recent developments point to a notable strategic shift. In January 2025, Windtree launched a new corporate strategy aimed at becoming a revenue-generating biotech through acquisitions of small companies and FDA-approved products, while continuing to advance its cardiovascular and oncology pipeline. In May and June 2025, the company reported first-quarter results and highlighted positive publication data for istaroxime in early cardiogenic shock, including progress on the SEISMiC C study. Windtree also entered into a March 2025 license and supply agreement with Evofem to supply Phexxi outside the United States, adding a commercial element to the story. Separately, 2025 press releases showed the company pursuing an unconventional BNB crypto treasury strategy, underscoring a corporate profile that is more dynamic—and more speculative—than a traditional biotech. ([ir.windtreetx.com](https://ir.windtreetx.com/news-releases/news-release-details/windtree-therapeutics-reports-first-quarter-2025-financial?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
